Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Gliflozins are a novel class of oral anti-diabetic drugs, acting as inhibitors of sodium-glucose
co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal …

Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has emerged
as a promising neuroprotective agent in murine models of epilepsy and obesity-induced …

Abstract Alzheimer's disease (AD), the most frequent cause of dementia, is escalating as a
global epidemic, and so far, there is neither cure nor treatment to alter its progression. The …

Background Inhibition of sodium-glucose cotransporter-2 (SGLT2) has received remarkable
attention due to the beneficial effects observed in diabetes mellitus, heart failure, and kidney …

Abstract Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share
common pathological features including inflammation, insulin signaling alterations, or …

Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of
insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion …

The most common cause of dementia, especially in elderly people, is Alzheimer's disease
(AD), with aging as its main risk factor. AD is a multifactorial neurodegenerative disease …

Empagliflozin, a selective sodium-glucose co-transporter-2 inhibitor, has been demonstrated
to provide additional non-glycemic benefits, including neuroprotection. Endoplasmic …

Initially discovered as an impurity in insulin preparations, our understanding of the
hyperglycaemic hormone glucagon has evolved markedly over subsequent decades. With …